Nirogacestat

OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment.

Side effects, and when to stop

The following serious adverse reactions are described elsewhere in the labeling:

Diarrhea [ see Warnings and Precautions ( 5.1 )]
Ovarian Toxicity [ see Warnings and Precautions ( 5.2 )]
Hepatotoxicity
Non-Melanoma Skin Cancers
Electrolyte Abnormalities [ see Warnings and Precautions ( 5.5 )]

Who should not take it

None.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Nirogacestat; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/nirogacestat
APA 7th: sofidex. (2026, August 3). Nirogacestat. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/nirogacestat
AMA 11th: Nirogacestat. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/nirogacestat

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.